

Arachidonic acid release and prostaglandin F_{2α} formation induced by phenylarsine oxide in PC12 cells: possible involvement of secretory phospholipase A₂ activity

Keiko Ohsawa^{a,1}, Asako Mori^{b,1}, Syunji Horie^a, Takeshi Saito^c, Yasunobu Okuma^b, Yasuyuki Nomura^b, Toshihiko Murayama^{a,*}

^aLaboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 263-8522, Japan

^bDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

^cLaboratory of Environmental Biology, Hokkaido University School of Medicine, Sapporo 060-8638, Japan

Received 16 July 2001; accepted 9 January 2002

Abstract

Activation of phospholipase A₂ (PLA₂) causing arachidonic acid (AA) release is involved in neuronal cell functions. Previously, we reported AA release and prostaglandin F_{2α} (PGF_{2α}) formation via activation of cytosolic PLA₂ by orthovanadate (Na₃VO₄), an inhibitor of tyrosine phosphatases, in rat pheochromocytoma PC12 cells. We investigated the effects of phenylarsine oxide (PAO), which reacts with sulfhydryl groups of proteins and thus acts as an inhibitor of tyrosine phosphatases, on AA release and PGF_{2α} formation in PC12 cells. PAO stimulated [³H]AA release from the prelabeled cells and PGF_{2α} formation. The PAO responses were dependent upon the concentrations used (10 μM to 0.5 mM) and on extracellular CaCl₂. [³H]AA release induced by PAO was decreased significantly by inhibition of secretory, but not cytosolic, PLA₂. [³H]AA release by PAO was not reversed by washing the cells, but the addition of dithiol compounds such as 2,3-dimercapto-1-propanol decreased the release from the PAO-treated cells. The existence of mRNA of types I_B and II_C secretory PLA₂ in PC12 cells was detected by reverse transcriptase–polymerase chain reaction using specific primers. Addition of secretory PLA₂ from bee venom to the assay mixture stimulated [³H]AA release, and PAO enhanced the response synergistically. The addition of 0.1 mM PAO directly enhanced the activity of secretory PLA₂ from bee venom. These findings suggest that PAO stimulates AA release and PGF_{2α} formation probably via activation of secretory PLA₂ in PC12 cells. © 2002 Elsevier Science Inc. All rights reserved.

Keywords: Phenylarsine oxide; Arachidonic acid; Prostaglandin F_{2α}; Secretory phospholipase A₂; PC12 cells

1. Introduction

PLA₂ catalyzes the hydrolysis of phospholipids at the *sn*-2 position to produce lysophospholipids and fatty acids such as AA [1–3]. Three types of PLA₂ have been identified: the 10- to 14-kDa secretory type, the 85- to 100-kDa cytosolic type, and the 80-kDa Ca²⁺-independent type. Secretory PLA₂s require Ca²⁺ at millimolar concentrations for their activation, and are stabilized by disulfide linkages but inactivated by reducing agents such as dithiothreitol [1,4]. Secretory PLA₂s are known to exist in both an

extracellular form in inflammatory fluids and a cell-associated form; some are involved in inflammatory responses, formation of PGs, and apoptosis [5–8]. Cytosolic Ca²⁺-dependent PLA₂ (type IV) exhibits a preference for unsaturated fatty acids such as AA in the *sn*-2 position of phospholipids, and is regulated by Ca²⁺ at ~micromolar concentrations and its phosphorylation.

Sulfhydryl-modifying reagents such as iodoacetamide react with the cysteine residues near the active center, and inactivate cytosolic PLA₂ activity [2,9]. Cytosolic PLA₂ plays an essential role in the production of lipid mediators in response to receptor-mediated cellular signaling events. Ca²⁺-independent PLA₂ possibly serves as a housekeeping enzyme involved in the remodeling of membrane phospholipids [2,3].

In the brain, AA and its metabolites such as PGs are formed upon PLA₂ activation and are involved in neuronal functions including long-term potentiation, ion channel

* Corresponding author. Tel.: +81-43-290-2922; fax: +81-43-290-3021.

E-mail address: murayama@p.chiba-u.ac.jp (T. Murayama).

¹ These authors contributed equally to this work.

Abbreviations: PLA₂, phospholipase A₂; AA, arachidonic acid; PGs, prostaglandins; PGF_{2α}, prostaglandin F_{2α}; PAO, phenylarsine oxide; RT-PCR, reverse transcriptase–polymerase chain reaction; [Ca²⁺]_i, intracellular free Ca²⁺ concentration.

activity, and neurotransmitter release [10]. In addition, activation of cytosolic PLA₂ after ischemia was suggested to play a role in the neuronal damage [11–13]. Secretory PLA₂s have also been known to be neurotoxic and promote neuronal injury [14,15]. Secretory PLA₂ is released from rat brain synaptosomes and PC12 cells (a neuronal cell line), and inhibitors of type II secretory PLA₂ suppress the release of neurotransmitters in PC12 cells [16,17]. The addition of secretory PLA₂ to PC12 cells accelerates AA release and apoptotic cell death induced by deprivation of nerve growth factor [18], and AA stimulates apoptosis accompanied by DNA laddering in GH3 cells, a rat pituitary cell line [19]. These previous findings suggested the involvement of both cytosolic and secretory PLA₂ in the regulation of neuronal cell functions, including cell death.

PAO, an arsine oxide derivative, interacts with vicinal dithiol-containing molecules including enzymes and transcription factors, and is also known as an inhibitor of tyrosine phosphatases [20–24]. Previously, we reported that orthovanadate (Na₃VO₄), a general potent inhibitor of tyrosine phosphatases, stimulates [³H]AA release and PGF_{2α} formation in PC12 cells probably via activation of cytosolic PLA₂ activity [25]. During this study, we screened various phosphatase inhibitors and found that PAO alone markedly stimulated AA release. Here we show that PAO stimulated AA release and PGF_{2α} formation in an extracellular CaCl₂-dependent manner in PC12 cells. Although washing the cells did not reverse the stimulatory effect of PAO, the effect of PAO was inhibited by dithiol compounds such as dithiothreitol and 2,3-dimercapto-1-propanol, but not by monothiol compounds. An inhibitor of secretory PLA₂, but not inhibitors of cytosolic and Ca²⁺-independent PLA₂s, decreased PAO-stimulated AA release. We confirmed the existence of mRNAs of group I_B and II_C secretory PLA₂ in PC12 cells by RT-PCR. These findings suggest that sulfhydryl modification of the secretory type of PLA₂ by PAO regulated AA release and PGF_{2α} formation in PC12 cells.

2. Materials and methods

2.1. Materials

[5,6,8,9,11,12,14,15-³H]AA (215 Ci/mmol, 7.96 TBq/mmol) was purchased from Amersham. Mastoparan and aristolochic acid were obtained from the Sigma Chemical Co. A screening kit for protein phosphatase inhibitors was purchased from Alomone Lab. PAO, 2,3-dimercapto-1-propanol, and thioglycerol were obtained from Wako. Dithiothreitol and 2-mercaptoproethanol were obtained from Nacalai. Arachidonyl trifluoromethyl ketone (AACOCF₃) and haloenol lactone suicide substrate [HELSS, *E*-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one] were obtained from Research Biochemicals and Biomol. Research Lab. Inc., respectively. Secretory

PLA₂ from bee venom was purchased from Cayman (Catalog No. 60500).

2.2. Cell culture and measurement of [³H]AA release

PC12 cells were cultured on collagen-coated dishes (collagen type I-coated, IWAKI) in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum, as reported previously [25,26]. [³H]AA release from prelabeled PC12 cells was determined as described previously [25,26] with minor modifications. In brief, PC12 cells on dishes were incubated with Dulbecco's modified Eagle's medium (0.2% serum) and 1 μCi/mL (37 kBq/mL) of [³H]AA for 24 hr. The labeled cells were detached from dishes by pipetting. The cells were washed and suspended in a modified Tyrode HEPES buffer [137 mM NaCl, 5 mM KCl, 5 mM glucose, 2 mM MgSO₄, 2 mM CaCl₂, 20 mM HEPES (pH 7.4)]. In some experiments, the cells were suspended in the CaCl₂- and MgSO₄-free Tyrode buffer and incubated for 5 min with 0.5 mM PAO. Cell suspensions (30–50 μg protein) were incubated with the indicated agents for 30 min at 37° in the presence of 0.1% fatty acid-free bovine serum albumin (Sigma A-6003). The total volume was 200 μL, and the reaction was terminated by the addition of 500 μL of ice-cold Ca²⁺-Mg²⁺-free Tyrode buffer containing 5 mM EDTA and 5 mM EGTA followed by centrifugation (8000 g, 30 sec) at 4°. The ³H content of the supernatant was estimated by liquid scintillation spectrometry. Values were calculated as percentages relative to the total incorporation of [³H]AA.

2.3. Measurement of PGF_{2α} formation in PC12 cells

Confluent PC12 cells on 22-mm dishes (12-well plate) were incubated with the indicated agents for 30 min at 37° in the Tyrode HEPES buffer (pH 7.4) containing 0.1% fatty acid-free albumin. The content of PGF_{2α} in the buffer after centrifugation (200 g, 30 sec, 4°) was determined using an enzyme immunoassay kit (Cayman Chemical).

2.4. RT-PCR analysis

Total RNA was prepared from PC12 cells using TRIzol reagent (Sigma, 1 mL/100 mm dish). Total RNA (1 μg) was reverse-transcribed in a mixture containing oligo(dT)12–18 primer and SuperScript™ RT (Gibco BRL). PCR was carried out in a 15 μL reaction volume containing 1.5 μL of cDNA mixture, 1× PCR buffer containing 1.5 mM MgCl₂, 200 μM of each dNTP, 20 μM of each primer, and 1 U of Taq DNA polymerase (Gibco BRL). The DNA was denatured for 10 min at 95° prior to each PCR cycle of 95° for 1 min, 50–62° (annealing) for 1 min, 72° (elongation) for 1 min. Following the last cycle, elongation was extended for an additional 7 min at 72° before refrigeration. The primers for type I_B secretory PLA₂ were: sense 5'-CGCCAAGATGAAACTC-

CTTC-3' and antisense 5'-TAGACAGGAAGTGGGGT-GAC-3' (expected product 471 bp); for type II_A secretory PLA₂ they were: sense 5'-AGTTTGGCAAATGATTCTG-3' and antisense 5'-TCTTTCAGCAACTGGCGTC-3' (expected product 372 bp); for type II_C secretory PLA₂ they were: sense 5'-TGAACCTGGCAGATGAAGGTG-3' and antisense 5'-GGCTCAGACTAGAGCAGGTG-3' (expected product 550 bp), as reported previously [27]. The number of cycles selected for each primer pair was found to produce a linear relationship between the input RNA and the resulting PCR products. The PCR products were analyzed by 6.5% non-denaturing polyacrylamide gel electrophoresis and visualized with ethidium bromide.

2.5. Statistics

Values are means \pm SEM of the indicated numbers (over three) of independent experiments performed in triplicate assays. In the case of multiple comparisons, the significance of differences was determined using one-way analysis of variance followed by Dunnett's or Tukey's test. For pairwise comparisons, Student's two-tailed *t*-test was used. *P* values at <0.05 were considered to be significant.

3. Results

3.1. Extracellular Ca²⁺-dependent [³H]AA release by PAO via secretory PLA₂ activation in PC12 cells

Previously, we reported that the addition of 5 mM Na₃VO₄ alone stimulates [³H]AA release for 20 min in PC12 cells [25]. Of the tyrosine phosphatase inhibitors examined, PAO, but neither sodium fluoride nor pyrophosphate, markedly stimulated [³H]AA release in PC12 cells. The addition of PAO to the assay mixture markedly stimulated [³H]AA release in a concentration-dependent manner (Fig. 1). In Ca²⁺-free and 0.2 mM EGTA-containing buffer, the effect of 0.5 mM PAO was not detected (Fig. 1).

Next, we investigated the effects of inhibitors of PLA₂ on 0.5 mM PAO-stimulated [³H]AA release in PC12 cells (Table 1). AACOCF₃ is a specific inhibitor of cytosolic PLA₂, and its inhibition of other types of PLA₂ is reduced by more than 1000-fold [28]. Previously, we reported that treatment for 10 min with 10 μ M AACOCF₃, the concentration at which it inhibits cytosolic PLA₂ but neither secretory PLA₂ nor Ca²⁺-independent PLA₂ [29], almost completely inhibits 20 μ M mastoparan-stimulated [³H]AA release induced by activation of cytosolic PLA₂ in PC12 cells [26]. The effect of 0.5 mM PAO, however, was not inhibited even by treatment with 30 μ M AACOCF₃ for 20 min. HELSS (10 μ M) is a potent and selective inhibitor of Ca²⁺-independent PLA₂ [3]. The effect of 0.5 mM PAO was not inhibited significantly by 10 μ M (data not shown) or 30 μ M HELSS (Table 1). Aristolochic acid is widely




Fig. 1. Extracellular Ca²⁺-dependent [³H]AA release by PAO in PC12 cells. The PC12 cells prelabeled with [³H]AA were washed three times by centrifugation with CaCl₂-free Tyrode HEPES buffer. For measurement of [³H]AA release, the cells were incubated for 30 min with vehicle or the indicated concentrations of PAO in the absence (●) or presence (○) of 2 mM CaCl₂. Reactions were terminated by the addition of 500 μ L of ice-cold Ca²⁺-, Mg²⁺-free Tyrode buffer containing 5 mM EDTA and 5 mM EGTA. In addition, EGTA (0.2 mM) was further added to the assay mixture. Values are means \pm SEM of 3 independent experiments done in triplicate. Key: (a) significantly different from vehicle, *P* < 0.05.

Table 1
Effects of PLA₂ inhibitors on PAO-stimulated [³H]AA release in PC12 cells

Treatment/addition	[³ H]AA release (% of total)	
	None	0.5 mM PAO
Experiment I		
None	1.97 \pm 0.13	7.67 \pm 0.24
AACOCF ₃ (30 μ M)	2.03 \pm 0.16	7.21 \pm 0.37
HELSS (30 μ M)	1.76 \pm 0.23	6.44 \pm 0.45
Experiment II		
None	1.84 \pm 0.32	6.42 \pm 0.25 (100)
Aristolochic acid (20 μ M)	1.59 \pm 0.31	4.44 \pm 0.53* (53.1 \pm 6.5*)

Prelabeled PC12 cells were preincubated with vehicle, 30 μ M AACOCF₃, or 30 μ M HELSS for 20 min (in Experiment I) or with vehicle or 20 μ M aristolochic acid for 90 min (in Experiment II). Then the washed cells were incubated with vehicle or 0.5 mM PAO for 30 min in the presence of the same concentrations of PLA₂ inhibitors. Since the inhibitory effect of aristolochic acid was partial and showed a variation among experiments, the values in parentheses are normalized as the percentage of 0.5 mM PAO-stimulated [³H]AA release from control cells. Values are means \pm SEM for 3 independent experiments done in triplicate.

* *P* < 0.05, significantly different from vehicle.

used as an inhibitor of secretory PLA₂ [6,30]. The effect of 0.5 mM PAO was partially, but significantly, inhibited by 20 μM aristolochic acid. Aristolochic acid did not inhibit the [³H]AA release induced by 30 μM mastoparan; the values were 10.2 ± 2.2 and 10.8 ± 2.6 (% of total, N = 4) in the absence and presence of 20 μM aristolochic acid, respectively. Treatment with higher concentrations of aristolochic acid (40 μM and over) did not show a significantly higher inhibitory effect (data not shown). These findings suggest that PAO stimulates secretory PLA₂ activity in PC12 cells, which requires Ca²⁺ at millimolar concentrations, and is inhibited by aristolochic acid.

3.2. Inhibition of PAO-stimulated [³H]AA release by vicinal dithiol compounds

PAO interacts with small molecular weight dithiol compounds such as dithiothreitol but hardly interacts with monothiol compounds [22,24]. Dithiol compounds such as dithiothreitol and 2,3-dimercapto-1-propanol at 1 mM, but not monothiol compounds such as thioglycerol and 2-mercaptopropanol, abolished the effect of 0.5 mM PAO on [³H]AA release (Table 2). Neither 2,3-dimercapto-1-propanol nor the monothiol compounds at 1 mM inhibited [³H]arachidonic acid release induced by 30 μM mastoparan via activation of cytosolic PLA₂ (Table 2). The effect of mastoparan was not inhibited by dithiothreitol (data not shown, but see Ref. [26]).

In the PAO-treated PC12 cells, which were first incubated with 0.5 mM PAO for 5 min in CaCl₂-free Tyrode buffer, washed with PAO-free buffer and then incubated without PAO in CaCl₂-containing buffer, [³H]AA release was significantly higher (6.84% of total) compared with control cells (1.52% of total), which were incubated 30 min with vehicle in CaCl₂-containing buffer (Table 3). The addition of 0.1 mM (data not shown) and 0.5 mM PAO

Table 2
Effects of thiol compounds on PAO-stimulated [³H]AA release in PC12 cells

Addition	[³ H]AA release (% of total)		
	None	0.5 mM PAO	30 μM Mastoparan
None	1.52 ± 0.18	6.94 ± 0.27*	7.99 ± 0.34*
DTT	1.38 ± 0.19	1.60 ± 0.29**	Not inhibited ^a
DMP	1.49 ± 0.09	2.28 ± 0.04**	6.61 ± 0.10
ME	1.45 ± 0.19	5.79 ± 0.25	7.33 ± 0.56
TG	1.49 ± 0.33	6.61 ± 0.37	7.35 ± 0.40

Prelabeled PC12 cells were treated with vehicle, 0.5 mM PAO, or 30 μM mastoparan for 30 min. The assay mixture was supplemented further with 1 mM thiol compounds or vehicle. The thiol compounds used were dithiols [dithiothreitol (DTT) and 2,3-dimercapto-1-propanol (DMP)] and monothiols [2-mercaptopropanol (ME) and thioglycerol (TG)]. Values are means ± SEM for 3 independent experiments done in triplicate.

^a Ref. [26].

* P < 0.001, significantly different from vehicle.

** P < 0.001, significantly different from values without thiol compounds.

Table 3

[³H]AA release in the PAO-treated PC12 cells and its inhibition by dithiol compounds

Addition	[³ H]AA release (% of total)	
	None	0.5 mM PAO
Control cells (Table 2)	1.52 ± 0.18	6.94 ± 0.27*
0.5 mM PAO-treated cells		
None	6.84 ± 1.57*	5.24 ± 1.12
DTT	2.61 ± 0.46**	3.03 ± 0.60
DMP	2.61 ± 0.46**	3.62 ± 0.37
ME	4.99 ± 0.92	3.54 ± 1.08
TG	4.85 ± 1.01	3.70 ± 1.85

Prelabeled PC12 cells were incubated with 0.5 mM PAO in CaCl₂-free buffer for 5 min. Cells were washed and finally incubated with 1 mM thiol compounds or vehicle in CaCl₂-containing buffer for 30 min with or without the addition of 0.5 mM PAO. The thiol compounds used were dithiols [dithiothreitol (DTT) and 2,3-dimercapto-1-propanol (DMP)] and monothiols [2-mercaptopropanol (ME) and thioglycerol (TG)]. Values are means ± SEM for 4 independent experiments done in triplicate.

* P < 0.01, significantly different from the value without PAO in the control cells.

** P < 0.05, significantly different from the values without thiol compounds.

into the assay mixture did not show an additive effect on [³H]AA release in the PAO-treated PC12 cells. Interestingly, [³H]AA release from the 0.5 mM PAO-treated cells was inhibited significantly by dithiol compounds (dithiothreitol and 2,3-dimercapto-1-propanol). The effects of the monothiol compounds were limited (Table 3).

3.3. Enhancement of [³H]AA release induced by exogenous addition of secretory PLA₂ from bee venom

Next we investigated the effect of the isolated secretory PLA₂ from bee venom (type III) on [³H]AA release in PC12 cells (Fig. 2). The addition of the secretory PLA₂ (0.1 μg/mL) to the assay mixture markedly stimulated [³H]AA release from the prelabeled PC12 cells, and the effect in the presence of 2 mM CaCl₂ was significantly higher than that in the Ca²⁺-free buffer. [³H]AA release induced by the addition of 0.5 μg/mL of secretory PLA₂ in the presence of CaCl₂ was 8.7 ± 0.7% (N = 3), which was similar to that by 0.1 μg/mL of secretory PLA₂. Interestingly, 0.5 mM PAO synergistically stimulated [³H]AA release induced by secretory PLA₂ (0.1 μg/mL). The synergistic effect of PAO on [³H]AA release was completely dependent upon extracellular CaCl₂ (Fig. 2) and was abolished by the addition of 1 mM 2,3-dimercapto-1-propanol and dithiothreitol (data not shown).

Next the effect of PAO on the activity of secretory PLA₂ was measured by using a secretory PLA₂ assay kit (Cayman). In the present conditions, an increase of absorbance units (A₄₁₄) by purified secretory PLA₂ from bee venom (40 ng) was linear at least for 10 min, and the value for 10 min was 0.5. The addition of 0.1 mM PAO to the assay mixture increased absorbance to 1.2 units. In the case of PC12 cell homogenates, however, we could not




Fig. 2. [³H]AA release by exogenous addition of secretory PLA₂ and its enhancement by PAO. The PC12 cells prelabeled with [³H]AA were washed three times by centrifugation with CaCl₂-free Tyrode HEPES buffer. The cells were incubated for 30 min with vehicle, 0.5 mM PAO, 0.1 µg/mL of secretory PLA₂ from bee venom, or the combination of PAO and secretory PLA₂ in the absence (hatched bars) or presence (open bars) of 2 mM CaCl₂. Reactions were terminated by the addition of 500 µL of ice-cold Ca²⁺-, Mg²⁺-free Tyrode buffer containing 5 mM EDTA and 5 mM EGTA. In addition, EGTA (0.2 mM) was further added to the assay mixture. Values are means ± SEM of 3 independent experiments done in triplicate. Key: (a) significantly different from the value in the absence of CaCl₂, $P < 0.01$; and (b) significantly different from the additive value by PAO and secretory PLA₂ from bee venom, $P < 0.01$.

Table 4
Increase in PGF_{2α} formation by PAO in PC12 cell culture medium

Addition	Increase in PGF _{2α} (% of control)	
	2 mM CaCl ₂	CaCl ₂ -free
None	100 (453 ± 87 pg/well/30 min)	100 (90 ± 26 pg/well/30 min)
PAO (0.1 mM)	987 ± 225*	232 ± 33*
PAO (0.5 mM)	2430 ± 529*	Not determined

PC12 cells on 22-mm dishes were incubated in Tyrode HEPES buffer containing 0.1% bovine serum albumin (fatty acid-free grade) for 30 min in the presence or absence of 2 mM CaCl₂. The indicated concentrations of PAO or vehicle were further added to the assay mixture. The content of PGF_{2α} in the buffer was assayed using an enzyme immunoassay kit. The content of PGF_{2α} in the buffer without cells was under the detection limit (<8 pg/mL). The absolute values of PGF_{2α} formation without PAO are shown in parentheses. Since PGF_{2α} formation in the buffer showed a wide variation, values are normalized as the percentage of basal PGF_{2α} formation without PAO. Values are means ± SEM for 3–4 independent experiments done in triplicate.

* $P < 0.05$, significantly different from vehicle.

determine the PLA₂ activity properly; factors such as glutathione in the cell homogenates probably disturbed the assay-system in the kit, and the increase of absorbance units was not linear (data not shown).

3.4. Increase in PGF_{2α} formation by PAO

Previously, we reported that the addition of Na₃VO₄ increases PGF_{2α} formation in the PC12 cell culture medium [25]. The addition of 0.1 and 0.5 mM PAO increased PGF_{2α} formation significantly (Table 4). In the absence of extracellular CaCl₂, PGF_{2α} formation in the medium was low; the value was 10–30% of that in the presence of 2 mM CaCl₂. In addition, the effect induced by 0.1 mM PAO in the absence of CaCl₂ was much less (200–300% of the control value without PAO) compared with that in the presence of CaCl₂ (Table 4). In a control experiment, the co-addition of 1 mM dithiothreitol alone had no effect on PGF_{2α} formation, whereas dithiothreitol inhibited 0.1 mM PAO-stimulated PGF_{2α} formation almost completely (80–110% of the control value without PAO) (data not shown).

3.5. Detection of type I_B and type II_C secretory PLA₂ transcripts in PC12 cells by RT-PCR

Both mRNA and protein of type II secretory PLA₂ were detected previously in PC12 cells [16,17]. Although type II secretory PLA₂ was divided into three subtypes (A, B, and C) [31], the subtype of PLA₂ in PC12 cells was not determined in their studies. We revealed the existence of




Fig. 3. Detection of secretory PLA₂ mRNA by RT-PCR in PC12 cells. Total RNA was isolated from PC12 cells and run in the presence of RT. In lanes 1, 2, and 3, the primers for type I_B, I_C, and I_A secretory PLA₂s were used, respectively. Lane 4 shows a 100 bp DNA ladder.

the transcript for type II_C, but not type II_A, secretory PLA₂ in PC12 cells by RT-PCR (Fig. 3). The transcript for type I_B secretory PLA₂ was also detected in PC12 cells.

4. Discussion

4.1. AA release via activation of secretory PLA₂ by PAO in PC12 cells

Previously, we reported that Na₃VO₄, a general inhibitor of protein tyrosine phosphatases, stimulates [³H]AA release and PGF_{2α} formation, and enhances ionomycin- and mastoparan-stimulated [³H]AA release via activation of cytosolic PLA₂ in PC12 cells [25]. In the process of that study, we examined the effects of various inhibitors of protein phosphatases, and found that PAO stimulated AA release and PGF_{2α} formation in PC12 cells. PAO, an arsine oxide derivative, forms stable ring structures with vicinal sulfhydryl groups of cellular proteins and enzymes [22,24], and thus PAO has been widely used as an inhibitor of protein tyrosine phosphatases [20,21,23]. However, the effects of PAO in the present study appeared to be derived from the activation of secretory PLA₂, but not cytosolic PLA₂. The reasons are as follows. First, [³H]AA release stimulated by PAO was almost completely dependent upon the existence of millimolar quantities of extracellular CaCl₂ (Fig. 1). In addition, PGF_{2α} formation induced by PAO (Table 4) was induced markedly in the CaCl₂-containing buffer. In contrast, Na₃VO₄ markedly stimulated [³H]AA release from PC12 cells treated with BAPTA-AM, a cell-permeable chelator of Ca²⁺, in Ca²⁺-free buffer [25]. Second, the effect of PAO on [³H]AA release was inhibited significantly by aristolochic acid (20 μM, an inhibitor of secretory PLA₂), but not by AACOCF₃ (30 μM, an inhibitor of Ca²⁺-dependent cytosolic PLA₂) (Table 1). Third, we confirmed the existence of secretory PLA₂ mRNA (type I_B and II_C) in PC12 cells by RT-PCR (Fig. 3). Fourth, PAO enhanced [³H]AA release induced by exogenous addition of purified secretory PLA₂ from bee venom (Fig. 2). These findings suggest that PAO causes AA release and PGF_{2α} formation by stimulation of secretory PLA₂ activity in PC12 cells. To our knowledge, the present study is the first showing AA release and PGF_{2α} formation by PAO in neuronal cells.

4.2. Possible mechanism(s) of activation of secretory PLA₂ in PC12 cells by PAO

Na₃VO₄ stimulates [³H]AA release probably via the tyrosine phosphorylation pathway and activation of cytosolic PLA₂ in PC12 cells [25]. In a preliminary experiment using immunoblotting with anti-phosphotyrosine antibody, incubation with 0.1 mM PAO for 10 min led to increases in phosphotyrosine accumulation in many protein bands in PC12 cells (data not shown). Yamamoto *et al.* [32] reported

that PAO induced tyrosine phosphorylation of protein kinase Cδ in CHO cells. Although activation of P_{2Y2} receptors by ATP stimulates tyrosine phosphorylation of protein kinase Cδ in PC12 cells [33], the addition of ATP or phorbol 12-myristate 13-acetate (an activator of classical and novel protein kinase Cs) did not stimulate [³H]AA release in PC12 cells [34]. In addition, treatment with 3 μM calphostin C, which inhibits noradrenaline release induced by protein kinase C activation in PC12 cells [35], did not inhibit [³H]AA release induced by 0.5 mM PAO (data not shown).

In several cells [36,37], PAO stimulated a concentration-dependent increase in the [Ca²⁺]_i. Since activity of secretory PLA₂s requires Ca²⁺ at millimolar concentrations, it is probable that PAO raises [Ca²⁺]_i levels locally and stimulates PLA₂ activity. However, the effects of ionomycin and KCl-induced depolarization on [³H]AA release were limited in PC12 cells, as previously reported [25,34]. Thus, the stimulatory effect of PAO on AA release did not appear to be due to an increase in [Ca²⁺]_i.

The stimulatory effect of PAO was not abolished in the cells first incubated with 0.5 mM PAO for 5 min and then washed with the PAO-free buffer (Table 3). [³H]AA release from the PAO-treated cells, which was significantly higher compared with that from the control cells, was inhibited by the addition of dithiol compounds (Table 3). The addition of PAO synergistically enhanced [³H]AA release induced by secretory PLA₂ from bee venom (Fig. 2), and dithiol compounds at 1 mM inhibited [³H]AA release by co-addition of secretory PLA₂ and 0.5 mM PAO (data not shown). As described in Section 3, PAO interacted directly with and activated type III secretory PLA₂ from bee venom. These findings suggest that the effect of PAO on AA release is due to the sulfhydryl modification of the target molecule(s), probably secretory PLA₂s in PC12 cells. Recently, it was reported that a PAO-binding protein (p7/p23) complex is a positive regulator of NADPH oxidase activation in bovine neutrophils and that PAO diminishes the optimal concentration of AA for maximal oxidase activation [38]. It should be determined whether PAO interacts directly with secretory PLA₂ and/or interacts with another molecule(s) regulating secretory PLA₂ activity in PC12 cells.

4.3. Neuronal cell functions of secretory PLA₂

An increase in cytosolic PLA₂ activities and PG and thromboxane production has been reported in numerous brain diseases [11–13]. Secretory PLA₂s are also present in the brain, and the expression of secretory PLA₂s is stimulated in the rat brain by ischemia/reperfusion [39] and in astrocytes by cytokines [40,41]. Kudo *et al.* [16] and Matsuzawa *et al.* [17] reported that type II secretory PLA₂ and dopamine are released after exocytotic stimulation with glutamate, and that dopamine release is inhibited by an inhibitor of type II PLA₂ (thielocin A1) in PC12

cells. However, in PC12 cells first incubated with PAO and then thoroughly washed with the PAO-free buffer, the stimulatory effect of PAO on [³H]AA release was still fully intact in the absence of PAO. Furthermore, we have reported that the addition of 50 mM KCl and receptor stimulation by ATP, which causes noradrenaline release [35], do not stimulate [³H]AA release from PC12 cells [34]. Thus, whether secretory PLA₂ is released into the extracellular medium by receptor stimulation, and the role of secretory PLA₂ on transmitter release from PC12 cells have not been established.

Secretory PLA₂s including venom toxins are known to be neurotoxic [15,39]. In PC12 cells undergoing apoptosis induced by deprivation of nerve growth factor and serum, the addition of type II secretory PLA₂ enhances arachidonic acid release [18]. In hamster kidney cells, however, transfection of type II_A secretory PLA₂ generated anti-apoptotic survival signals [6]. Research on apoptosis and/or survival of PC12 cells induced by PAO is currently in progress in our laboratory.

Acknowledgments

This work was supported, in part, by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (T. Murayama, S. Horie, and T. Saito).

References

- [1] Kudo I, Murakami M, Hara S, Inoue K. Mammalian non-pancreatic phospholipase A₂. *Biochim Biophys Acta* 1993;117:217–31.
- [2] Leslie CC. Properties and regulation of cytosolic phospholipase A₂. *J Biol Chem* 1997;272:16709–12.
- [3] Balsinde J, Dennis EA. Function and inhibition of intracellular calcium-independent phospholipase A₂. *J Biol Chem* 1997;272:16069–72.
- [4] Tischfield JA. A reassessment of the low molecular weight phospholipase A₂ gene family in mammals. *J Biol Chem* 1997;272:17247–50.
- [5] Hanasaki K, Ono T, Saiga A, Morioka Y, Ikeda M, Kawamoto K, Higashino K, Nakano K, Yamada K, Ishizaka J, Arita H. Purified group X secretory phospholipase A₂ induced prominent release of arachidonic acid from human myeloid leukemia cells. *J Biol Chem* 1999;274:34203–11.
- [6] Zhang Y, Lemasters J, Herman B. Secretory group IIA phospholipase A₂ generates anti-apoptotic survival signals in kidney fibroblasts. *J Biol Chem* 1999;274:27726–33.
- [7] Murakami M, Kambe T, Shimbara S, Higashino K, Hanasaki K, Arita H, Horiguchi M, Arai M, Arai H, Inoue K, Kudo I. Different functional aspects of the group II subfamily (type IIA and V) and type X secretory phospholipase A₂s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. *J Biol Chem* 1999;274:31435–44.
- [8] Balsinde J, Balboa MA, Yedgar S, Dennis EA. Group V phospholipase A₂-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D₁ macrophages. *J Biol Chem* 2000;275:4783–6.
- [9] Li B, Xia L, Krantz A, Yuan Z. Site-directed mutagenesis of Cys³²⁴ and Cys³³¹ in human cytosolic phospholipase A₂: locus of action of thiol modification reagents leading to inactivation of cPLA₂. *Biochemistry* 1996;35:3156–61.
- [10] Piomelli D. Eicosanoids in synaptic transmission. *Crit Rev Neurobiol* 1994;5:274–80.
- [11] Owada Y, Tominaga T, Yoshimoto T, Kondo H. Molecular cloning of rat cDNA for cytosolic phospholipase A₂ and the increased gene expression in the dentate gyrus following transient forebrain ischemia. *Mol Brain Res* 1994;25:364–8.
- [12] Clemens JA, Stephenson DT, Smalstig EB, Roberts EF, Johnstone EM, Sharp JD, Little SP, Kramer RM. Reactive glia express cytosolic phospholipase A₂ after transient global forebrain ischemia in the rat. *Stroke* 1996;27:527–35.
- [13] Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A₂. *Nature* 1997;390:622–5.
- [14] Clapp LE, Klette KL, DeCoster MA, Bernton E, Petras JM, Dave JR, Laskosky MS, Smallridge RC, Tortella FC. Phospholipase A₂-induced neurotoxicity in vitro and in vivo in rats. *Brain Res* 1995;693:101–11.
- [15] Kolko M, DeCoster MA, Rodriguez de Turco EB, Bazan NG. Synergy by secretory phospholipase A₂ and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. *J Biol Chem* 1996;271:32722–8.
- [16] Kudo I, Matsuzawa A, Imai K, Murakami M, Inoue K. Function of type II phospholipase A₂ in dopamine secretion by rat neuronal PC12 cells. *J Lipid Mediat Cell Signal* 1996;14:25–31.
- [17] Matsuzawa A, Murakami M, Atsumi G, Imai K, Prados P, Inoue K, Kudo I. Release of secretory phospholipase A₂ from rat neuronal cells and its possible function in the regulation of catecholamine secretion. *Biochem J* 1996;318:701–9.
- [18] Atsumi G, Murakami M, Tajima M, Shimbara S, Hara N, Kudo I. The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A₂ to liberate arachidonic acid. *Biochim Biophys Acta* 1997;1349:43–54.
- [19] Yasuda Y, Yoshinaga N, Murayama T, Nomura Y. Inhibition of hydrogen peroxide-induced apoptosis but not arachidonic acid release in GH3 cell by EGF. *Brain Res* 1999;850:197–206.
- [20] Bernier N, Laird DM, Lane ND. Insulin-activated tyrosine phosphorylation of a 15-kilodalton protein in intact 3T3-L1 adipocytes. *Proc Natl Acad Sci USA* 1987;84:1844–8.
- [21] Garcia-Morales P, Minami Y, Luong E, Klausner RD, Samelson LE. Tyrosine phosphorylation in T cells is regulated by phosphatase activity: studies with phenylarsine oxide. *Proc Natl Acad Sci USA* 1990;87:9255–9.
- [22] Kaled E, Walfish PG, Gitler C. Arsenical-based affinity chromatography of vicinal dithiol-containing proteins: purification of L1210 leukemia cytoplasmic proteins and the recombinant rat c-erb A β_1 T₃ receptor. *Anal Biochem* 1993;212:325–34.
- [23] Mahboubi K, Young W, Ferreri NR. Tyrosine phosphatase-dependent tyrosine kinase independent induction of nuclear factor- κ B by tumor necrosis factor- α : effects on prostaglandin endoperoxide synthase-2 mRNA accumulation. *J Pharmacol Exp Ther* 1998;285:862–8.
- [24] Oda M, Sakitani K, Kaibori M, Inoue T, Kamiyama Y, Okumura T. Vicinal dithiol-binding agent, phenylarsine oxide, inhibits inducible nitric-oxide synthase gene expression at a step of nuclear factor- κ B DNA binding in hepatocytes. *J Biol Chem* 2000;275:4369–73.
- [25] Mori A, Yasuda Y, Murayama T, Nomura Y. Enhancement of arachidonic acid release and prostaglandin F_{2 α} formation by Na₃VO₄ in PC12 cells and GH3 cells. *Eur J Pharmacol* 2001;417:19–25.
- [26] Thang SH, Yasuda Y, Umezawa M, Murayama T, Nomura Y. Inhibition of phospholipase A₂ activity by S-nitroso-cysteine in a cyclic GMP-independent manner in PC12 cells. *Eur J Pharmacol* 2000;395:183–91.
- [27] Ramanadham S, Ma Z, Arita H, Zhang S, Turk J. Type IB secretory phospholipase A₂ is contained in insulin secretory granules of pan-

- creatic islet β -cell and is co-secreted with insulin from glucose-stimulated islets. *Biochim Biophys Acta* 1998;1390:301–12.
- [28] Bartoli F, Lin HK, Ghomashchi F, Gelb MH, Jain MK, Apitz-Castro R. Tight binding inhibitors of 85-kDa phospholipase A₂ but not 14-kDa phospholipase A₂ inhibit release of free arachidonate in thrombin-stimulated human platelets. *J Biol Chem* 1994;269:15625–30.
- [29] Atsumi G, Tajiama M, Hadano Y, Nakatani M, Murakami I, Kudo I. Fas-induced arachidonic acid release is mediated by Ca²⁺-independent phospholipase A₂ but not cytosolic phospholipase A₂, which undergoes proteolytic inactivation. *J Biol Chem* 1998;273:13870–7.
- [30] Martínez-Salgado C, Rodríguez-Barbero A, Rodríguez-Puyol D, Pérez de Lema G, López-Novoa JM. Involvement of phospholipase A₂ in gentamicin-induced rat mesangial cell activation. *Am J Physiol* 1997;273:F60–6.
- [31] Balsinde J, Balboa MA, Insel PA, Dennis EA. Regulation and inhibition of phospholipase A₂. *Annu Rev Pharmacol Toxicol* 1999;39:175–89.
- [32] Yamamoto T, Matsuzaki H, Konishi H, Ono Y, Kikkawa U. H₂O₂-induced tyrosine phosphorylation of protein kinase C δ by a mechanism independent of inhibition of protein-tyrosine phosphatase in CHO and COS-7 cells. *Biochem Biophys Res Commun* 2000;273:960–6.
- [33] Soltoff SP, Avraham H, Avraham S, Cantley LC. Activation of P_{2Y2} receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C. *J Biol Chem* 1998;273:2653–60.
- [34] Murayama T, Oda H, Watanabe A, Nomura Y. ATP receptor-mediated increase of Ca ionophore-stimulated arachidonic acid release from PC12 pheochromocytoma cells. *Jpn J Pharmacol* 1995;69:43–51.
- [35] Oda H, Murayama T, Nomura Y. Inhibition of protein kinase C-dependent noradrenaline release by wortmannin in PC12 cells. *Arch Biochem Biophys* 1996;337:96–102.
- [36] Fleming I, Fisslthaler B, Busse R. Interdependence of calcium signaling and protein tyrosine phosphorylation in human endothelial cells. *J Biol Chem* 1996;271:11009–15.
- [37] Lajas AI, Pozo MJ, Camello PJ, Salido GM, Pariente JA. Phenylarsine oxide evokes intracellular calcium increases and amylase secretion in isolated rat pancreatic acinar cells. *Cell Signal* 1999;11:727–34.
- [38] Doussière J, Bouzidi F, Vignais PV. A phenylarsine oxide-binding protein of neutrophil cytosol, which belongs to the S100 family, potentiates NADPH oxidase activation. *Biochem Biophys Res Commun* 2001;285:1317–20.
- [39] Lauritzen I, Heurteaux C, Lazdunski M. Expression of group II phospholipase A₂ in rat brain after severe forebrain ischemia and in endotoxic shock. *Brain Res* 1994;651:353–6.
- [40] Oka S, Arita H. Inflammatory factors stimulate expression of group II phospholipase A₂ in rat cultured astrocytes. *J Biol Chem* 1991;266:9956–60.
- [41] Thomas G, Bertrand F, Saunier B. The differential regulation of group II_A and group V low molecular phospholipase A₂ in cultured rat astrocytes. *J Biol Chem* 2000;275:10876–86.